Blood vessel growth in benign tumours can illuminate malignant ones

Santoro, Helen

doi:10.1038/d41586-022-03136-2

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor vessels were clearly labeled in vivo via BSA-Gd even under 3T MR, being greatly superior to Gd-DTPA (Figure G). These findings are highly significant for the research on tumor development, treatment selection, determination of efficacy, and prognosis. , Taking advantage of the labeling kidney vasculature and tumor vasculature, we examined the labeling effect of BSA-Gd on the kidney in situ tumor vasculature. Preoperative clarification of the peritumor vascular distribution is essential for guiding partial nephrectomy.…”

Section: Resultsmentioning

confidence: 99%

“…High-resolution imaging of the microvessels is critical for monitoring and treating a variety of diseases, designing the surgical route, and planning preoperative embolization. , Magnetic resonance angiography (MRA) is one of the most powerful tools for vascular imaging in a radiation-free manner. − However, the commonly used gadolinium-based contrast agents for high-resolution MRA present limitations in terms of the effective time window and longitudinal relaxivity ( r 1 ) . Recording vessels with a diameter of about a few hundred micrometers is a formidable task even with the most advanced MRA techniques, for example, complete recognition of the clinically significant circle of Willis and tumor vessels. − To reduce the scanning time and administration dose, another area of concern is the realization of one-time, wide-area imaging . Identification of arteries and veins through dynamic contrast-enhanced MRA is considered equally critical for the diagnosis of diseases including arteriovenous malformations .…”

Section: Introductionsmentioning

confidence: 99%

See 1 more Smart Citation

Amorphous Albumin Gadolinium-Based Nanoparticles for Ultrahigh-Resolution Magnetic Resonance Angiography

Liu,

Wei

et al. 2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Magnetic resonance angiography (MRA) contrast agents are extensively utilized in clinical practice due to their capability of improving the image resolution and sensitivity. However, the clinically approved MRA contrast agents have the disadvantages of a limited acquisition time window and high dose administration for effective imaging. Herein, albumin-coated gadolinium-based nanoparticles (BSA-Gd) were meticulously developed for in vivo ultrahighresolution MRA. Compared to Gd-DTPA, BSA-Gd exhibits a significantly higher longitudinal relaxivity (r 1 = 76.7 mM −1 s −1 ), nearly 16-fold greater than that of Gd-DTPA, and an extended blood circulation time (t 1/2 = 40 min), enabling a dramatically enhanced high-resolution imaging of microvessels (sub-200 μm) and low dose imaging (about 1/16 that of Gd-DTPA). Furthermore, the clinically significant fine vessels were successfully mapped in large mammals, including a circle of Willis, kidney and liver vascular branches, tumor vessels, and differentiated arteries from veins using dynamic contrast-enhanced MRA BSA-Gd, and have superior imaging capability and biocompatibility, and their clinical applications hold substantial promise.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionsmentioning

confidence: 99%

Amorphous Albumin Gadolinium-Based Nanoparticles for Ultrahigh-Resolution Magnetic Resonance Angiography

Liu,

Wei

et al. 2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

A mitochondrion-targeted cyanine agent for NIR-II fluorescence-guided surgery combined with intraoperative photothermal therapy to reduce prostate cancer recurrence

Liu,

Chang,

Chen

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

Poorly identified tumor boundaries and nontargeted therapies lead to the high recurrence rates and poor quality of life of prostate cancer patients. Near-infrared-II (NIR-II) fluorescence imaging provides certain advantages, including high resolution and the sensitive detection of tumor boundaries. Herein, a cyanine agent (CY7-4) with significantly greater tumor affinity and blood circulation time than indocyanine green was screened. By binding albumin, the absorbance of CY7-4 in an aqueous solution showed no effects from aggregation, with a peak absorbance at 830 nm and a strong fluorescence emission tail beyond 1000 nm. Due to its extended circulation time (half-life of 2.5 h) and high affinity for tumor cells, this fluorophore was used for primary and metastatic tumor diagnosis and continuous monitoring. Moreover, a high tumor signal-to-noise ratio (up to ~ 10) and excellent preferential mitochondrial accumulation ensured the efficacy of this molecule for photothermal therapy. Therefore, we integrated NIR-II fluorescence-guided surgery and intraoperative photothermal therapy to overcome the shortcomings of a single treatment modality. A significant reduction in recurrence and an improved survival rate were observed, indicating that the concept of intraoperative combination therapy has potential for the precise clinical treatment of prostate cancer. Graphical Abstract

show abstract

Blood vessel growth in benign tumours can illuminate malignant ones

Cited by 2 publications

References 0 publications

Amorphous Albumin Gadolinium-Based Nanoparticles for Ultrahigh-Resolution Magnetic Resonance Angiography

Amorphous Albumin Gadolinium-Based Nanoparticles for Ultrahigh-Resolution Magnetic Resonance Angiography

A mitochondrion-targeted cyanine agent for NIR-II fluorescence-guided surgery combined with intraoperative photothermal therapy to reduce prostate cancer recurrence

Contact Info

Product

Resources

About